PO-22 | Impact of sleep disorders on anti-CGRP monoclonal antibodies treatment response in migraine: a cross-sectional study
Abstract
Background: The relationship between migraine and sleep disorders (SDs) is well-established, but only few studies have investigated the impact of anti-CGRP monoclonal antibodies (mAbs) on sleep. To our knowledge, no study has specifically analysed the potential role of sleep in influencing the response to treatment with anti-CGRP mAbs. Aim of our study is to assess sleep quality and screen for SDs in patients undergoing treatment with anti-CGRP mAbs and to investigate the potential predictive role of these parameters in treatment response.
Methods: We included patients aged >18 years undergoing FRANCAVIg anti-CGRP mAbs treatment at standard dosages for at least three months with adequate compliance. Patients were grouped as follows after data collection: responders (>50% reduction in mean headache days (MHDs) compared to baseline) and non-responders (75% reduction in MHDs. During the visit, we obtained anthropometric measurements (weight, height, and neck circumference), and patients completed a structured interview assessing sleep quality, chronotype, and screening for major SDs using the following questionnaires: Pittsburgh Sleep Quality Index (PSQI), Epworth Sleep Scale (ESS), Fatigue Assessement Scale (FAS), Morning-Eveningness Questionnaire (MEQ), STOP-Bang, Restless Leg Syndrome assessment test. Numeric variables were compared by means of one-way analysis of variance Kruskal-Wallis test or Mann-Whitney U-test. Categorial variables were analyzed by means of table of…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 50 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.